rezafungin Updated Oct 24
Watch for the specific PDUFA date announcement (Q1 2027) for the REZZAYO prophylaxis sNDA, which is the next major binary catalyst. The stock trades at ~$7.85 with ~$15.33 analyst target (95% upside) but carries ~20% short interest, suggesting a potential squeeze setup if the sNDA is approved. Monitor Q3 earnings on Nov 11, 2026 for REZZAYO revenue trajectory in the currently approved indications.
- REZZAYO is already FDA-approved (March 2023) for candidemia and invasive candidiasis, de-risking the platform. The sNDA for prophylaxis of invasive fungal disease was granted FDA Priority Review in October 2026 with a PDUFA target in Q1 2027, a major label expansion catalyst within ~3-5 months.
- Analyst consensus is overwhelmingly bullish: 11 buy/strong buy, 1 hold, 0 sell, with a mean price target of $15.33 vs current ~$7.85, implying ~95% upside. Needham reiterated Buy on Oct 19, 2026, and Oppenheimer initiated at Outperform on Sep 23, 2026.
- Phase III ReSPECT data met its primary endpoint (non-inferior fungal-free survival at Day 90), and the drug showed a favorable safety profile with fewer toxicity-related discontinuations and drug-drug interactions vs standard therapy.
- High short interest (~19.79% of estimated shares outstanding as of Sep 30, 2026) and elevated FINRA short-volume ratio (~57% over 61 sessions) indicate heavy bearish positioning that could reflect skepticism about the prophylaxis expansion opportunity or competitive pressure from cheaper generic echinocandins (micafungin, caspofungin).
- The Q1 2027 PDUFA is a binary event, if FDA issues a Complete Response Letter or requests additional data for the prophylaxis sNDA, the stock could sell off sharply given the high expectations baked into analyst targets of $15+.
- The Phase III ReSPECT trial showed 60.7% fungal-free survival at Day 90 for rezafungin vs 59.0% for standard therapy, a narrow 1.7 percentage point margin that may not convince FDA reviewers of meaningful superiority over existing prophylaxis options.